Syneos Health, Inc. operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a strategic collaboration with Elligo Health Research. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-876-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.39 billion
Profitability
Miscellaneous
Employees21,000
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) released its earnings results on Monday, March, 18th. The company reported $0.89 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.73 by $0.16. The company had revenue of $1.15 billion for the quarter, compared to analysts' expectations of $1.15 billion. Syneos Health had a return on equity of 9.60% and a net margin of 0.55%. The business's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.70 EPS. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY19 earnings guidance on Monday, March, 18th. The company provided EPS guidance of $3.03-3.23 for the period, compared to the Thomson Reuters consensus estimate of $3.07. The company issued revenue guidance of $4.62-4.73 billion, compared to the consensus revenue estimate of $4.69 billion.Syneos Health also updated its FY 2019 guidance to $3.03-3.23 EPS.
What price target have analysts set for SYNH?
10 equities research analysts have issued twelve-month target prices for Syneos Health's shares. Their predictions range from $45.00 to $60.00. On average, they anticipate Syneos Health's stock price to reach $53.7778 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
News articles about SYNH stock have been trending neutral this week, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syneos Health earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Syneos Health's key competitors?
Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
What other stocks do shareholders of Syneos Health own?
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Dr. Michael Gibertini, Pres of Clinical Devel. for Therapeutic Bus. Units (Age 61)
- Mr. Michael Adam Bell, Consultant (Age 63)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
- Mr. Robert Parks, Exec. VP & Chief Accounting Officer
- Dr. Judith Ng-Cashin, Chief Scientific Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Thomas H Lee Partners LP (18.61%), BlackRock Inc. (8.20%), Mackenzie Financial Corp (3.10%), Dimensional Fund Advisors LP (1.49%), Principal Financial Group Inc. (1.29%) and Northern Trust Corp (1.11%). Company insiders that own Syneos Health stock include Alistair Macdonald, Christopher L Gaenzle, Gregory S Rush, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which major investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Monarch Partners Asset Management LLC, Dimensional Fund Advisors LP, Mesirow Financial Investment Management Equity Management, Bank of America Corp DE, Barclays PLC, GW&K Investment Management LLC and Mackay Shields LLC. Company insiders that have sold Syneos Health company stock in the last year include Alistair Macdonald and H Lee Equity Fund Vi Thomas. View Insider Buying and Selling for Syneos Health.
Which major investors are buying Syneos Health stock?
SYNH stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Mackenzie Financial Corp, Principal Financial Group Inc., Thrivent Financial for Lutherans, Amundi Pioneer Asset Management Inc., D. E. Shaw & Co. Inc. and Phocas Financial Corp.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $50.35.
How big of a company is Syneos Health?
Syneos Health has a market capitalization of $5.22 billion and generates $4.39 billion in revenue each year. The company earns $-138,460,000.00 in net income (profit) each year or $2.62 on an earnings per share basis. Syneos Health employs 21,000 workers across the globe.
What is Syneos Health's official website?
How can I contact Syneos Health?
Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
